• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pineapple Financial Authorizes $3 Million Share Repurchase Program

By: Newsfile
March 12, 2026 at 08:30 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Buyback Authorization Reflects Management Commitment to Building Long-Term Shareholder Value

Toronto, Ontario--(Newsfile Corp. - March 12, 2026) - Pineapple Financial Inc. (NYSE American: PAPL) ("Pineapple" or "the Company"), a leading fintech platform, today announced that its Board of Directors has authorized a share repurchase program for up to US$3,000,000 of the Company's common shares in the open market.

"Our decision to authorize this share repurchase program reflects our conviction in Pineapple's long-term strategy and the strength of the operating model we've built," said Shubha Dasgupta, Chief Executive Officer of Pineapple Financial. "We believe that our current market valuation does not fully reflect the progress we've made across our mortgage platform, our data and tokenization initiatives, and our Digital Asset Treasury. This authorization will provide flexibility to deploy capital opportunistically when it enhances long-term shareholder value, while we remain focused on execution, liquidity discipline, and building a more durable earnings profile over time."

The Company intends to begin repurchasing shares in the first half of 2026. The timing and price of repurchases, as well as the actual number of shares repurchased under the program, will be at the discretion of the Company and will depend on a variety of factors, including general market conditions, the stock price, regulatory requirements and limitations, trading blackout periods, corporate liquidity requirements and priorities, and other factors.

About Pineapple Financial Inc.

Pineapple Financial Inc. is an award-winning fintech and leading Canadian mortgage brokerage network, focusing on both the long-term success of agents and brokers as well as the overall experience of homeowners. With hundreds of brokers within the network, Pineapple creates cutting-edge cloud-based tools and AI-driven systems to enable its brokers to help Canadians realize their dream of owning a home. Pineapple is active within the community and is proud to sponsor charities across Canada to improve the lives of fellow Canadians.

Safe Harbor Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. They are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and economic needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, fluctuations in the market price of INJ and any associated impairment charges that we may incur as a result of a decrease in the market price of INJ below the value at which INJ is carried on our balance sheet; changes in the accounting treatment relating to our INJ holdings; the Company's financial condition, customer acceptance of our INJ treasury strategy, and other factors discussed in the "Risk Factors" section of the registration statements, and periodic reports filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results. It encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov.

Media Contact:

KCSA Strategic Communications
Kristin Cwalinski
pineapple@kcsa.com

Investor Relations:

KCSA Strategic Communications
Jack Perkins
pineapple@kcsa.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288209

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗
Today 6:02 EDT
Via MarketBeat
Topics Intellectual Property
Tickers ARGX
News headline image
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗
Today 5:02 EDT
Via MarketBeat
Tickers ARCT
News headline image
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference ↗
Today 1:02 EDT
Via MarketBeat
Topics Artificial Intelligence ETFs
Tickers AMGN
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
Today 0:02 EDT
Via MarketBeat
Tickers ALVO
News headline image
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
June 04, 2026
Via MarketBeat
Tickers ALT

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.79
+0.00 (0.00%)
AAPL  311.23
+0.00 (0.00%)
AMD  523.20
+0.00 (0.00%)
BAC  54.17
+0.00 (0.00%)
GOOG  369.27
+0.00 (0.00%)
META  627.57
+0.00 (0.00%)
MSFT  428.05
+0.00 (0.00%)
NVDA  218.66
+0.00 (0.00%)
ORCL  236.34
+0.00 (0.00%)
TSLA  418.45
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap